These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

232 related items for PubMed ID: 11641240

  • 1. Suppression of experimental myasthenia gravis, a B cell-mediated autoimmune disease, by blockade of IL-18.
    Im SH, Barchan D, Maiti PK, Raveh L, Souroujon MC, Fuchs S.
    FASEB J; 2001 Oct; 15(12):2140-8. PubMed ID: 11641240
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Protective potential of experimental autoimmune myasthenia gravis in Lewis rats by IL-10-modified dendritic cells.
    Duan RS, Adikari SB, Huang YM, Link H, Xiao BG.
    Neurobiol Dis; 2004 Jul; 16(2):461-7. PubMed ID: 15193302
    [Abstract] [Full Text] [Related]

  • 8. The limitation of IL-10-exposed dendritic cells in the treatment of experimental autoimmune myasthenia gravis and myasthenia gravis.
    Xiao BG, Duan RS, Zhu WH, Lu CZ.
    Cell Immunol; 2006 Jun; 241(2):95-101. PubMed ID: 17005165
    [Abstract] [Full Text] [Related]

  • 9. Immunosuppression and induction of anergy by CTLA4Ig in vitro: effects on cellular and antibody responses of lymphocytes from rats with experimental autoimmune myasthenia gravis.
    McIntosh KR, Linsley PS, Drachman DB.
    Cell Immunol; 1995 Nov; 166(1):103-12. PubMed ID: 7585970
    [Abstract] [Full Text] [Related]

  • 10. The Th2 cytokine IL-4 is not required for the progression of antibody-dependent autoimmune myasthenia gravis.
    Balasa B, Deng C, Lee J, Christadoss P, Sarvetnick N.
    J Immunol; 1998 Sep 15; 161(6):2856-62. PubMed ID: 9743346
    [Abstract] [Full Text] [Related]

  • 11. Immunosuppression of rat myasthenia gravis by oral administration of a syngeneic acetylcholine receptor fragment.
    Maiti PK, Feferman T, Im SH, Souroujon MC, Fuchs S.
    J Neuroimmunol; 2004 Jul 15; 152(1-2):112-20. PubMed ID: 15223243
    [Abstract] [Full Text] [Related]

  • 12. Animal models of myasthenia gravis.
    Christadoss P, Poussin M, Deng C.
    Clin Immunol; 2000 Feb 15; 94(2):75-87. PubMed ID: 10637092
    [Abstract] [Full Text] [Related]

  • 13. Activation of the adenosine A2A receptor attenuates experimental autoimmune myasthenia gravis severity.
    Li N, Mu L, Wang J, Zhang J, Xie X, Kong Q, Tang W, Yao X, Liu Y, Wang L, Wang G, Wang D, Jin L, Sun B, Li H.
    Eur J Immunol; 2012 May 15; 42(5):1140-51. PubMed ID: 22539289
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Mucosal tolerance to experimental autoimmune myasthenia gravis is associated with down-regulation of AChR-specific IFN-gamma-expressing Th1-like cells and up-regulation of TGF-beta mRNA in mononuclear cells.
    Ma CG, Zhang GX, Xiao BG, Wang ZY, Link J, Olsson T, Link H.
    Ann N Y Acad Sci; 1996 Feb 13; 778():273-87. PubMed ID: 8610980
    [Abstract] [Full Text] [Related]

  • 17. Blocking of IL-6 suppresses experimental autoimmune myasthenia gravis.
    Aricha R, Mizrachi K, Fuchs S, Souroujon MC.
    J Autoimmun; 2011 Mar 13; 36(2):135-41. PubMed ID: 21193288
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.